The Competition and Markets (Authority) has concluded following new evidence, that extra remedies in London's private healthcare market such as price controls would not be proportionate as part of its investigation into the UK private healthcare market.
Two of the CMA members dissented from this decision. Insurer Bupa described the final decision from the watchdog as "extraordinary" and it "had failed to find a solution." The Competition Commission, a predecessor body of the Competition and Markets Authority (CMA), started a market investigation into private healthcare in April 2012, which reported in April 2014, immediately after the establishment of the CMA. The report concluded that certain features of the markets for privately-funded...
Comparison services join forces
COVER podcast #2
3% cashback each month
'You can tell it's general election season'